Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Filing Names

Csl Limited
Csl Limited_20100114

Csl Limited patents

Recent patent applications related to Csl Limited. Csl Limited is listed as an Agent/Assignee. Note: Csl Limited may have other listings under different names/spellings. We're not affiliated with Csl Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Csl Limited-related inventors

Covalent complex of von willebrand factor and factor viii, compositions, and uses relating thereto

The present invention relates to a covalent complex of von willebrand factor (vwf) and factor viii, wherein the complex is modified such that it has an extended half-life in vivo. The invention further relates to a method of producing the complex, as well as the therapeutic or prophylactic use of the complex for treating or preventing bleeding events.. ... Csl Limited

High affinity antibody antagonists of interleukin-13 receptor alpha 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of il-13rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hil-13rα1 activity. ... Csl Limited

Method of treatment of philadelphia chromosome positive leukemia

The invention provides a method for the treatment of ph+ leukemia in a patient comprising administering to the patient (i) a bcr-abl tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of ph+ leukemia in a patient; and a composition for the treatment of ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). ... Csl Limited

Factor viii formulation

The invention relates to factor viii compositions and their use.. . ... Csl Limited

Antibodies against g-csfr and uses thereof

The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.. . ... Csl Limited

Reconstituted high density lipoprotein formulation and production method thereof

A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as apoai or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/l and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. ... Csl Limited

Modified von willebrand factor

The present invention provides a modified polypeptide which binds factor viii. The modified polypeptide comprises a sequence as shown in seq id no:3 in which the sequence comprises at least a modification at position 1 or 3 such that the modified polypeptide binds to factor viii with an off rate at least 5 fold lower than a reference polypeptide comprising an unmodified seq id no:3.. ... Csl Limited

Production of recombinant von willebrand factor in a bioreactor

The present invention relates to improved methods for the recombinant production of von willebrand factor (vwf) in a bioreactor by separating different multimeric forms of vwf with different molecular weight during fermentation.. . ... Csl Limited

Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor

The present invention relates to dosing regimens with half-life extended factor viia (fviia) for prophylactic and “on-demand” treatment of bleeding, as well as for preventing a bleeding episode during or after surgery in patients with congenital or acquired bleeding disorders. The present invention further relates to the use of half-life extended fviia for treating or preventing blood loss in patients without bleeding disorders in situations of hemorrhage, i.e., due to trauma or surgery. ... Csl Limited

Anti-tumor compositions and uses thereof

The present invention provides a composition for raising an immune response against a tumor. The composition comprises at least one tumor antigen, a saponin-based adjuvant, a tlr ligand and a flt3 ligand.. ... Csl Limited

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Csl Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Csl Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by